Clinical study to evaluate the role of basti karma (enema therapy) and virechan karma (purgation therapy) in hyperuricemia.
- Conditions
- Health Condition 1: E790- Hyperuricemia without signs of inflammatory arthritis and tophaceous disease
- Registration Number
- CTRI/2024/07/069925
- Lead Sponsor
- Ayurvedic and Unani Tibbia College and Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Patients attending out patient department with Sr. Uric Acid levels greater than 7.0mg/dl will be
enrolled in the study.
Patients who are contraindicated for Basti karma will not be included in Group A and for those who are contraindicated for Virechan karma will not be included in Group B. For both groups: Rectal prolapse, Fever, Pregnant and lactating mothers etc. For Group A: Udar rog, intestinal perforation, intestinal obstruction etc. For Group B: Loss of bowel control, atisara(diarrhea) etc
Known case of Rheumatoid Arthritis, Psoriatic Arthritis
Patients with renal or hepatic impairment (Sr creatinine greater than 1.8mg/dl along with Sr Urea greater than 60 mg/dl, SGOT and SGPT greater than Five times of upper limit Patients having LDL and Triglycerides greater than two times of upper limit
Patients with co-morbid conditions such as Hypertension grade 2 greater than equal to 160/100mm of Hg) or more, Diabetes Mellitus (having HbA1c greater than 7.5% with or without hyperglycemicmedications
Patients who are on anti tubercular or anti retroviral medication
Patients requiring emergency treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of patients showing improvement in the level of Sr. Uric acid <br/ ><br>post Basti karma and Virechan karma. <br/ ><br>Timepoint: At baseline. <br/ ><br>16th day <br/ ><br>31st day
- Secondary Outcome Measures
Name Time Method Assessment of features of vatarakta in patients of Hyperuricemia.Timepoint: At baseline <br/ ><br>16th day <br/ ><br>31st day;The proportion of patients showing changes in the inflammatory cytokine IL-6 & CRP post Basti karma & Virechan karma.Timepoint: At baseline <br/ ><br>31st day